
Charles B. Simone, II, MD, FASTRO, FACRO
New York Proton Center, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA
Charles B. Simone, II, MD, FACRO is Research Professor and Chief Medical Officer of the New York Proton Center and Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy, reirradiation, and stereotactic body radiation therapy, and in the development of innovative clinical trial strategies in thoracic oncology.
Prior to coming to NYPC, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at University of Pennsylvania and residency in radiation oncology at the National Cancer Institute (NCI), NIH, where he served as chief resident.
Dr. Simone is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who has published >600 scientific articles and chapters, given >525 scientific lectures to national/international audiences, and is the national Principal Investigator or Co-Chair of 8 NIH-funded cooperative group trials (5 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time Association of Residents in Radiation Oncology Educator of the Year Award winner. Dr. Simone is the Proton Collaborative Group (PCG) Board President. He Chairs the American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee, ASTRO Blue Ribbon Lung Panel, NRG Oncology Particle Therapy Work Group, PCG Lung Committee, American Radium Society (ARS) Appropriate Use Criteria Thoracic Committee, Particle Therapy Co-Operative Group (PTCOG) Thoracic Subcommittee, American College of Radiation Oncology (ACRO) Scientific Program Committee, NCI/Radiosurgery Society GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group, Varian FlashForward Consortium Scientific Committee, and Varian Proton Connect Users Group. He is Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Frontiers in Oncology, Translational Lung Cancer Research, Cancers, Journal of Thoracic Disease, Annals of Translational Medicine, Therapeutic Radiology and Oncology, Shanghai Chest, Journal of Xiangya Medicine, and AME Medical Journal.
Editorial Board
Terms of Appointment: August 2018 - August 2020; October 2020 - September 2022; October 2022 - September 2024; October 2024 - December 2026